BRAF and cancer: Briefly, ADT-007 showed potent allele-specific activity across a broad panel of RAS-mutant cancer cell lines including HCT116 (KRASG13D), MIA PaCa-2 (KRASG12C), PANC-1 (KRASG12D), SW480 (KRASG12V), and A549 (KRASG12S), while displaying little to no activity in RAS wild-type, BRAF-mutant lines such as HT29 and BxPC-3.